Publications by authors named "K J Kapples"

A new class of potent dopamine D(4) antagonists was discovered with selectivity over dopamine D(2) and the alpha-1 adrenoceptor. The lead compound was discovered by screening our compound collection. The structure-activity relationships of substituted isoindoline rings and the chirality about the hydroxymethyl side chain were explored.

View Article and Find Full Text PDF

A novel series of substituted (pyrroloamino)pyridines was synthesized, and the compounds were evaluated for cholinomimetic-like properties in vitro (inhibition of [3H]quinuclidinyl benzilate binding) and in vivo (reversal of scopolamine-induced dementia) as potential agents for the treatment of Alzheimer's disease. Compounds displaying significant activity were more broadly evaluated, which revealed the presence of a desirable adrenergic component of activity. The synthesis and structure-activity relationships for this series is presented, along with the biological profiles of selected compounds.

View Article and Find Full Text PDF

4-Amino-3-pyridyl carbamates (2a-c) were synthesized as potential acetylcholinesterase inhibitors and acetylcholine releasers on the basis of the reported activity of the analogous N-(4-amino-3-pyridyl)-N',N'-dimethylurea (1). Although 4-amino-3-pyridyl N,N-dimethylcarbamate (2b) showed good cholinesterase inhibition [concentration that elicited a 50% reduction in the maximal enzyme response (IC50) was 13.4 microM], it had no effect on the stimulated release of [3H]acetylcholine from rat striatal slices.

View Article and Find Full Text PDF
Article Synopsis
  • A series of 9-amino-1,2,3,4-tetrahydroacridin-1-ols was synthesized, showing potential as acetylcholinesterase inhibitors related to tacrine, which may help in Alzheimer's disease treatment.
  • In animal models, two specific compounds (1a and 1p) demonstrated effectiveness in reversing memory deficits caused by drug-induced impairments.
  • Both compounds exhibit lower toxicity compared to tacrine and are currently undergoing different phases of clinical trials for Alzheimer's disease.
View Article and Find Full Text PDF